Abstract
Molecular testing for anomalies, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase (ALK) rearrangement, is part of the current standard of care for non-small cell lung cancer, particularly adenocarcinoma. ALK rearrangement occurs most frequently in adenocarcinoma cells and rarely in non-adenocarcinoma cells. We herein report a rare case of pleomorphic lung carcinoma with ALK rearrangement in both its adenocarcinoma and spindle cell components. This case suggests the possibility of ALK rearrangement in pleomorphic carcinoma.
MeSH terms
-
Adenocarcinoma / diagnosis*
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / genetics
-
Aged
-
Anaplastic Lymphoma Kinase
-
Antineoplastic Agents / administration & dosage
-
Carcinoma, Non-Small-Cell Lung / diagnosis*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Cisplatin / administration & dosage
-
ErbB Receptors / genetics*
-
Female
-
Gene Rearrangement
-
Humans
-
Lung Neoplasms / diagnosis*
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics
-
Receptor Protein-Tyrosine Kinases / genetics*
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives
-
Vinorelbine
Substances
-
Antineoplastic Agents
-
Vinblastine
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
EGFR protein, human
-
ErbB Receptors
-
Receptor Protein-Tyrosine Kinases
-
Cisplatin
-
Vinorelbine